Pre‐eclampsia screening in Denmark ( PRESIDE ): national validation study
Ultrasound in Obstetrics & Gynecology · 2023-06 · 61 (6) · 682-690
DOI: 10.1002/uog.26183 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Ultrasound in Obstetrics & Gynecology, online erschienen am 05.05.2023. Verfasst von I Riishede und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Prenatal Diagnosis, Pre-Eclampsia. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal, Doctor Sofus Carl Emil and wife Olga Friis' Grant, The Jascha Foundation.
Abstract (Originalsprache)
Objectives
To investigate the predictive performance of the Fetal Medicine Foundation (FMF) first‐trimester screening algorithm for pre‐eclampsia in a Danish population and compare screening performance with that of the current Danish strategy, which is based on maternal risk factors.
Methods
This was a prospective study of women with a singleton pregnancy attending for their first‐trimester ultrasound scan and screening for aneuploidies at six Danish university hospitals between May 2019 and December 2020. Prenatal data on maternal characteristics and medical history were recorded, and measurements of mean arterial pressure (MAP), uterine artery pulsatility index (UtA‐PI), serum pregnancy‐associated plasma protein‐A (PAPP‐A) and serum placental growth factor (PlGF) were collected without performing a risk assessment for pre‐eclampsia. Information on acetylsalicylic acid use was recorded. After delivery, pregnancy outcome, including gestational age at delivery and pre‐eclampsia diagnosis, was recorded. Pre‐eclampsia risk assessment for each woman was calculated blinded to outcome using the FMF screening algorithm following adjustment to the Danish population. Detection rates (DRs) of the FMF algorithm were calculated for a fixed screen‐positive rate (SPR) of 10% and for the SPR achieved in the current Danish screening.
Results
A total of 8783 pregnant women were included, with a median age of 30.8 (interquartile range (IQR), 28.1–33.9) years. The majority were white (95%), naturally conceiving (90%), non‐smokers (97%) and had no family history of pre‐eclampsia (96%). The median body mass index was 23.4 (IQR, 21.2–26.6) kg/m 2 . A complete risk assessment including maternal characteristics, MAP, UtA‐PI, PlGF and PAPP‐A was available for 8156 women (92.9%). In these women, UtA‐PI was measured bilaterally with a median value of 1.58 (IQR, 1.27–1.94) and the median resting MAP of 80.5 (IQR, 76.1–85.4) mmHg in two consecutive measurements. Among these, 303 (3.7%) developed pre‐eclampsia, including 55 (0.7%) cases of pre‐eclampsia with delivery < 37 weeks of gestation and 16 (0.2%) cases of pre‐eclampsia with delivery < 34 weeks. At a SPR of 10%, combined screening using the FMF algorithm based on maternal characteristics, MAP, UtA‐PI, PlGF and PAPP‐A had a DR of 77.4% (95% CI, 57.6–97.2%) for pre‐eclampsia with delivery < 34 weeks, 66.8% (95% CI, 54.4–79.1%) for pre‐eclampsia with delivery < 37 weeks and 44.1% (95% CI, 38.5–49.7%) for pre‐eclampsia with delivery at any gestational age. The current Danish screening strategy using maternal risk factors detected 25.0% of women with pre‐eclampsia with delivery < 34 weeks and 19.6% of women with pre‐eclampsia with delivery < 37 weeks at a SPR of 3.4%. When applying the FMF algorithm including maternal characteristics, MAP, UtA‐PI and PlGF at the fixed SPR of 3.4%, the DRs were 60.5% (95% CI, 36.9–84.1%) for PE with delivery < 34 weeks and 45.2% (95% CI, 32.0–58.5%) for PE with delivery < 37 weeks.
Conclusion
In this large Danish multicenter study, the FMF algorithm based on maternal characteristics, MAP, UtA‐PI, PlGF and PAPP‐A predicted 77.4% of cases with pre‐eclampsia with delivery < 34 weeks and 66.8% of cases with pre‐eclampsia with delivery < 37 weeks of gestation at a SPR of 10%, suggesting that the performance of the algorithm in a Danish cohort matches that in other populations. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Obstetrics, Center of Fetal Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Biochemistry, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Department of Obstetrics and Gynecology, Fetal Medicine Unit, Odense University Hospital, Odense, Denmark.
- Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
- Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark.
ORCID-Profile: I Riishede
Förderung
- A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond til almene Formaal
- Doctor Sofus Carl Emil and wife Olga Friis' Grant
- The Jascha Foundation
- The Research Fund between Copenhagen University Hospital Rigshospitalet and Odense University Hospital
- The Research Fund of Copenhagen University Hospital Rigshospitalet
- The Research Fund of The Capital Region of Denmark
Zitieren
APA
Riishede, I., Rode, L., Sperling, L., Overgaard, M., Ravn, J. D., Sandager, P., Skov, H., Wagner, S. R., Nørgaard, P., Clausen, T. D., Jensen, C. A. J., Pihl, K., Jørgensen, F. S., Munk, J. K., Zingenberg, H. J., Pedersen, N. G., Andersen, M. R., Wright, A., Wright, D., …, & Ekelund, C. K. (2023). Pre‐eclampsia screening in Denmark ( PRESIDE ): national validation study. Ultrasound in Obstetrics & Gynecology, 61(6), 682-690. https://doi.org/10.1002/uog.26183
Vancouver
Riishede I, Rode L, Sperling L, Overgaard M, Ravn JD, Sandager P, et al. Pre‐eclampsia screening in Denmark ( PRESIDE ): national validation study. Ultrasound in Obstetrics & Gynecology. 2023;61(6):682-690. doi:10.1002/uog.26183
BibTeX
@article{Riishede2023,
author = {Riishede, I and Rode, L and Sperling, L and Overgaard, M and Ravn, J D and Sandager, P and Skov, H and Wagner, S R and Nørgaard, P and Clausen, T D and Jensen, C A Juel and Pihl, K and Jørgensen, F S and Munk, J K and Zingenberg, H J and Pedersen, N G and Andersen, M R and Wright, A and Wright, D and Tabor, A and Ekelund, C K},
title = {Pre‐eclampsia screening in Denmark ( PRESIDE ): national validation study},
journal = {Ultrasound in Obstetrics & Gynecology},
year = {2023},
volume = {61},
number = {6},
pages = {682--690},
doi = {10.1002/uog.26183}
}
EUVIMED